4//SEC Filing
Jones David Scott 4
Accession 0001562180-24-000785
CIK 0001314102other
Filed
Jan 28, 7:00 PM ET
Accepted
Jan 29, 5:54 PM ET
Size
15.2 KB
Accession
0001562180-24-000785
Insider Transaction Report
Form 4
Jones David Scott
SVP & Chief Commercial Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2024-01-26−16,413→ 68,742 totalExercise: $3.26Exp: 2033-01-05→ Common Stock (16,413 underlying) - Sale
Common Stock
2024-01-26$25.45/sh−16,413$417,653→ 47,566 total - Sale
Common Stock
2024-01-26$25.27/sh−9,604$242,717→ 37,962 total - Exercise/Conversion
Common Stock
2024-01-26$12.90/sh+9,604$123,892→ 47,566 total - Exercise/Conversion
Common Stock
2024-01-26$3.26/sh+16,413$53,506→ 63,979 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-01-26−9,604→ 8,721 totalExercise: $12.90Exp: 2030-02-28→ Common Stock (9,604 underlying)
Footnotes (4)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $26.00. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F2]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $25.88. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F3]The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 28, 2020
- [F4]The option to purchase will vest and become exercisable as follows: 25% at January 6th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years.
Documents
Issuer
EyePoint Pharmaceuticals, Inc.
CIK 0001314102
Entity typeother
Related Parties
1- filerCIK 0001779458
Filing Metadata
- Form type
- 4
- Filed
- Jan 28, 7:00 PM ET
- Accepted
- Jan 29, 5:54 PM ET
- Size
- 15.2 KB